Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Significant Increase in Short Interest

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) was the target of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 4,800 shares, agrowthof71.4% from the July 15th total of 2,800 shares. Approximately0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 8,500 shares, the days-to-cover ratio is presently 0.6 days. Based on an average daily trading volume, of 8,500 shares, the days-to-cover ratio is presently 0.6 days. Approximately0.0% of the company’s shares are short sold.

Adlai Nortye Trading Down 3.4%

Shares of ANL opened at $1.69 on Monday. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.02. Adlai Nortye has a twelve month low of $1.10 and a twelve month high of $3.89. The firm’s 50 day moving average price is $1.55 and its two-hundred day moving average price is $1.87.

Analyst Ratings Changes

Separately, HC Wainwright downgraded Adlai Nortye from a “buy” rating to a “neutral” rating in a research note on Monday, June 2nd.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.